Fosravuconazole

Fosravuconazole is a triazole antifungal agent. In Japan, it is approved for the treatment of onychomycosis, a fungal infection of the nail. It is a prodrug that is converted into ravuconazole.
Drugs for Neglected Diseases Initiative and the Japanese pharmaceutical company Eisai found that fosravuconazole works as a treatment for mycetoma, a serious condition. The Phase II clinical trial found that oral fosravuconazole was safe, patient-friendly, and effective in treating eumycetoma. Eumycetoma mainly affects young adults in poorer, rural areas; the standard treatment is itraconazole, which is much more expensive at about US$2,000 for a year than fosravuconazole and unaffordable, and not available in all endemic countries.